Schema of complement therapeutic targets under study for autoimmune hemolytic anemia. Complement inhibitors are summarized according to their target and the step of the complement pathway it involves. Ecullizumab inhibits C5; pegcetacoplan inhibits C3 and C3 convertase activity; sutimlimab and riliprubart inhibit C1s of the classic pathway; empasiprubart and Nab1B10 inhibit C2 targeting the classic and lectin pathway; C1-INH inhibits C1r, C1s, and mannan-binding lectin serine proteases 1 and 2, targeting the classic and lectin pathway. Professional illustration by Somersault18:24.